SCHEMBL1800218

SCHEMBL1800218

CC1CC(C)Oc2cscc2O1

nearest known ligand 0.31

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.31
NOS1 P29475 1/20 0.31
NOS2 P35228 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5316569 0.79
SCHEMBL4853891 0.76 PRKCA (0.30)
SCHEMBL7135539 0.76
SCHEMBL2933289 0.76
SCHEMBL5022973 0.72
SCHEMBL15437703 0.70 TNKS (0.31)
SCHEMBL14587297 0.65
SCHEMBL4254682 0.65
SCHEMBL1936840 0.64
SCHEMBL9229849 0.63 SMN1; SMN2 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220017689-A1 ALL-DONOR BLACK ELECTROCHROMIC POLYMER AND METHOD FOR PREPARING SAME AMBILIGHT INC. 2022-01-20 US disclosed
US-20110201826-A1 CONJUGATED POLYMERS FROM SUBSTITUTED 3,4-PROPYLENEDIOXYTHIOPHENE, COMPOSITIONS, METHOD OF MAKING, AND USE THEREOF SOTZING GREGORY A 2011-08-18 US disclosed
US-20110201826-A1 CONJUGATED POLYMERS FROM SUBSTITUTED 3,4-PROPYLENEDIOXYTHIOPHENE, COMPOSITIONS, METHOD OF MAKING, AND USE THEREOF SOTZING GREGORY A 2011-08-18 US disclosed
US-20110201826-A1 CONJUGATED POLYMERS FROM SUBSTITUTED 3,4-PROPYLENEDIOXYTHIOPHENE, COMPOSITIONS, METHOD OF MAKING, AND USE THEREOF SOTZING GREGORY A 2011-08-18 US disclosed
US-7951902-B2 Conjugated polymers from substituted 3,4-propylenedioxythiophene, compositions, method of making, and use thereof THE UNIVERSITY OF CONNECTICUT (US) 2011-05-31 US disclosed
US-7951902-B2 Conjugated polymers from substituted 3,4-propylenedioxythiophene, compositions, method of making, and use thereof THE UNIVERSITY OF CONNECTICUT (US) 2011-05-31 US disclosed
US-7951902-B2 Conjugated polymers from substituted 3,4-propylenedioxythiophene, compositions, method of making, and use thereof THE UNIVERSITY OF CONNECTICUT (US) 2011-05-31 US disclosed
US-20090203873-A1 CONJUGATED POLYMERS FROM SUBSTITUTED 3,4-PROPYLENEDIOXYTHIOPHENE, COMPOSITIONS, METHOD OF MAKING, AND USE THEREOF THE UNIVERSITY OF CONNECTICUT 2009-08-13 US disclosed
US-20090203873-A1 CONJUGATED POLYMERS FROM SUBSTITUTED 3,4-PROPYLENEDIOXYTHIOPHENE, COMPOSITIONS, METHOD OF MAKING, AND USE THEREOF THE UNIVERSITY OF CONNECTICUT 2009-08-13 US disclosed
US-20090203873-A1 CONJUGATED POLYMERS FROM SUBSTITUTED 3,4-PROPYLENEDIOXYTHIOPHENE, COMPOSITIONS, METHOD OF MAKING, AND USE THEREOF THE UNIVERSITY OF CONNECTICUT 2009-08-13 US disclosed
WO-2009094361-A2 CONJUGATED POLYMERS FROM SUBSTITUTED 3,4-PROPYLENEDIOXYTHIOPHENE, COMPOSITIONS, METHOD OF MAKING, AND USE THEREOF UNIVERSITY OF CONNECTICUT (US) 2009-07-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201826-A1 CONJUGATED POLYMERS FROM SUBSTITUTED 3,4-PROPYLENEDIOXYTHIOPHENE, COMPOSITIONS, METHOD OF MAKING, AND USE THEREOF MPST, TST, PNMT NOS3 785/4885NOS1 3456/4885NOS2 2562/4885
US-20090203873-A1 CONJUGATED POLYMERS FROM SUBSTITUTED 3,4-PROPYLENEDIOXYTHIOPHENE, COMPOSITIONS, METHOD OF MAKING, AND USE THEREOF MPST, TST, PNMT NOS3 785/4885NOS1 3456/4885NOS2 2562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.